Safety, immunogenicity and duration of immunity elicited by an inactivated bovine ephemeral fever vaccine

PLoS One. 2013 Dec 12;8(12):e82217. doi: 10.1371/journal.pone.0082217. eCollection 2013.

Abstract

Bovine ephemeral fever (BEF) is an economically important viral vector-borne cattle disease. Several live-attenuated, inactivated and recombinant vaccines have been tested, demonstrating varying efficacy. However, to the best of our knowledge, duration of immunity conferred by an inactivated vaccine has never been reported. In the last decade, Israel has faced an increasing number of BEF outbreaks. The need for an effective vaccine compatible with strains circulating in the Middle East region led to the development of a MONTANIDE™ ISA 206 VG (water-in-oil-in-water), inactivated vaccine based on a local strain. We tested the safety, immunogenicity and duration of immunity conferred by this vaccine. The induced neutralizing antibody (NA) response was followed for 493 days in 40 cows vaccinated by different protocols. The vaccine did not cause adverse reactions or a decrease in milk production. All cows [except 2 (6.7%) which did not respond to vaccination] showed a significant rise in NA titer of up to 1:256 following the second, third or fourth booster vaccination. Neutralizing antibody levels declined gradually to 1:16 up to 120 days post vaccination. This decline continued in cows vaccinated only twice, whereas cows vaccinated 3 or 4 times showed stable titers of approximately 1:16 for up to 267 days post vaccination. At least three vaccinations with the inactivated BEF vaccine were needed to confer long-lasting immunity. These results may have significant implications for the choice of vaccination protocol with inactivated BEF vaccines. Complementary challenge data should however be added to the above results in order to determine what is the minimal NA response conferring protection from clinical disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Neutralizing / immunology
  • Body Temperature
  • Cattle
  • Ephemeral Fever / immunology*
  • Ephemeral Fever / prevention & control*
  • Ephemeral Fever / virology
  • Immunity*
  • Time Factors
  • Vaccination
  • Vaccines, Inactivated / adverse effects*
  • Vaccines, Inactivated / immunology*
  • Viral Vaccines / adverse effects*
  • Viral Vaccines / immunology*

Substances

  • Antibodies, Neutralizing
  • Vaccines, Inactivated
  • Viral Vaccines

Grants and funding

This study was supported by grants from the Israeli Dairy Board (grant no. 705-0016-08) and from the Israel Science Foundation (grant no. 1009/11). OAB was partly supported by the "Hoffman Leadership and Responsibility" fellowship program at the Hebrew University of Jerusalem, Israel. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.